GlassScriptPhysician profile
Bijan Bastani
NPI 1780629345
$7,656.29
in general payments reported to CMS, 2019-2025
24 companies · $1,158 in 2025
The $1,158 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,345 · 2020: $222 · 2021: $79.97 · 2022: $1,011 · 2023: $2,202 · 2024: $1,639 · 2025: $1,158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,892 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,892.47 |
| Education | $105.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,036.91 | 2019-2025 | Rexulti |
| Abbvie INC. | $988.60 | 2022-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $871.62 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $833.96 | 2019-2024 | Spravato, Invega Sustenna, Invega |
| Lundbeck LLC | $647.02 | 2019-2025 | Rexulti |
| Axsome Therapeutics, INC. | $629.19 | 2023-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $326.49 | 2019-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $311.45 | 2019-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $305.45 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $261.68 | 2019-2024 | Lybalvi, Aristada |
| Allergan, INC. | $228.63 | 2019-2020 | |
| Bausch Health US, LLC | $223.63 | 2019-2024 | Aplenzin, Wellbutrin |
| Idorsia Pharmaceuticals US INC | $183.94 | 2023 | Quviviq |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $141.46 | 2019-2024 | |
| Neos Therapeutics, LP | $123.73 | 2019-2025 | Adzenys Xr-Odt |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $118.86 | 2023-2025 | Azstarys, Azstarys |
| Neurocrine Biosciences, INC. | $108.35 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $104.68 | 2019-2025 | Austedo Xr, Austedo Xr |
| Ironshore Pharmaceuticals INC. | $46.86 | 2023-2024 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $40.24 | 2025 | Jornay Pm |
| Noven Therapeutics, LLC | $33.21 | 2023 | Xelstrym |
| Supernus Pharmaceuticals, INC. | $31.65 | 2023-2025 | Qelbree, Qelbree |
| Shire North American Group INC | $30.95 | 2019 | |
| Tris Pharma INC | $27.73 | 2023-2024 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bijan Bastani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.